Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

被引：0

作者：

Nieves Martinez Chanza

Louisa Soukane

Philippe Barthelemy

Aurélien Carnot

Thierry Gil

Vinciane Casert

Vincent Vanhaudenarde

Brieuc Sautois

Lionel Staudacher

Jan Van den Brande

Stephane Culine

Emmanuel Seront

Marco Gizzi

Simone Albisinni

Thibault Tricard

Jean Christophe Fantoni

Marianne Paesmans

Rafael Caparica

Thierry Roumeguere

Ahmad Awada

机构：

[1] Jules Bordet Institute,Hopital Erasme

[2] Université Libre de Bruxelles,Clinique Sainte

[3] Université Libre de Bruxelles,Elisabeth

[4] Institut de Cancérologie Strasbourg Europe ICANS,undefined

[5] Centre Oscar Lambret,undefined

[6] Centre Hospitalier Universitaire de Ambrois Paré,undefined

[7] UCL,undefined

[8] University Hospital of Liege (CHU Sart Tilman),undefined

[9] Hopital Paris Saint Joseph,undefined

[10] University Hospital Antwerp,undefined

[11] UZA,undefined

[12] Hopital Saint-Louis,undefined

[13] Hopital de Jolimont,undefined

[14] Grand Hopital de Charleroi,undefined

来源：

BMC Cancer | / 21卷

关键词：

Avelumab; Bladder cancer; Checkpoint inhibitor; Immunotherapy; Neoadjuvant; PD-1 blockade; Urothelial carcinoma;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Seligson, Nathan D.
Chen, James L.
Goodrich, Austin C.
Van Tine, Brian A.
Campbell, Jordan D.
Richards, Allison L.
Antonescu, Cristina R.
Liebner, David A.
Milhem, Mohammed M.
Streicher, Howard
Tap, William D.
Schwartz, Gary K.
George, Suzanne
D'Angelo, Sandra P.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
[22] Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
Funt, Samuel A.
Lattanzi, Michael
Whiting, Karissa
Al-Ahmadie, Hikmat
Quinlan, Colleen
Teo, Min Yuen
Lee, Chung-Han
Aggen, David
Zimmerman, Danielle
McHugh, Deaglan
Apollo, Arlyn
Durdin, Trey D.
Truong, Hong
Kamradt, Jeffrey
Khalil, Maged
Lash, Bradley
Ostrovnaya, Irina
McCoy, Asia S.
Hettich, Grace
Regazzi, Ashley
Jihad, Marwah
Ratna, Neha
Boswell, Abigail
Francese, Kaitlyn
Yang, Yuanquan
Folefac, Edmund
Herr, Harry W.
Donat, S. Machele
Pietzak, Eugene
Cha, Eugene K.
Donahue, Timothy F.
Goh, Alvin C.
Huang, William C.
Bajorin, Dean F.
Iyer, Gopa
Bochner, Bernard H.
Balar, Arjun V.
Mortazavi, Amir
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (12) : 1312 - +
[23] BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)
Glynne-Jones, R.
Hall, M. R.
Lopes, A.
Pearce, S.
Goh, V
Bosompem, S.
Bridgewater, J.
Chau, I
Wasan, H.
Moran, B.
Melcher, L.
West, N. P.
Quirke, P.
Wong, W-L
Beare, S.
Hava, N.
Duggan, M.
Harrison, M.
HELIYON, 2018, 4 (09):
[24] A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
Small, Eric J.
Fontana, Joseph
Tannir, Nizar
DiPaola, Robert S.
Wilding, George
Rubin, Mark
Iacona, Renee Bailey
Kabbinavar, Fairooz F.
BJU INTERNATIONAL, 2007, 100 (04) : 765 - 769
[25] NEOADJUVANT INTENSIVE INTRAVESICAL MITOMYCIN C REGIMEN VERSUS STANDARD SCHEDULE FOR NON MUSCLE INVASIVE BLADDER CANCER. RANDOMIZED PHASE II STUDY
Rocchini, L.
Pellucchi, F.
Ibrahim, B.
Maccagnano, C.
Freschi, M.
Zanni, G.
Villa, L.
Gandaglia, G.
Capogrosso, P.
Passoni, N. M.
Fossati, N.
Colombo, R.
EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 148 - 148
[26] Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
Fountzilas, George
Kotoula, Vassiliki
Pectasides, Dimitrios
Kouvatseas, George
Timotheadou, Eleni
Bobos, Mattheos
Mavropoulou, Xanthipi
Papadimitriou, Christos
Vrettou, Eleni
Raptou, Georgia
Koutras, Angelos
Razis, Evangelia
Bafaloukos, Dimitrios
Samantas, Epaminontas
Pentheroudakis, George
Skarlos, Dimosthenis V.
PLOS ONE, 2013, 8 (07):
[27] THE POTENTIAL IMPACT OF NEOADJUVANT CHEMOTHERAPY ON PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR NON-UROTHELIAL MUSCLE INVASIVE BLADDER CANCER
Gelpi-Hammerschmidt, Francisco
Rodriguez, Dayron
Tinay, Ilker
Allard, Christopher
Hanna, Nawar
Chang, Steven
Trinh, Quoc-Dien
Preston, Mark
JOURNAL OF UROLOGY, 2016, 195 (04): : E8 - E8
[28] GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) plus /- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)-GETUG AFU V07.
Gross-Goupil, Marine
Frison, Eric
Roubaud, Guilhem
Flechon, Aude
Calcagno, Fabien
Rolland, Frederic
Joly, Florence
Raymond, Anne-Aurelie
Chotard, Guillaume
Barthelemy, Philippe
Pouessel, Damien
Thibault, Constance
Culine, Stephane
Linassier, Claude
Ravaud, Alain
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 637 - 637
[29] Outcome of bladder preservation therapy (BPT) in non-metastatic muscle invasive bladder cancer. Analysis of the Hospital Sultanah Aminah experience
Alagappan, K.
Omar, S.
Han, P. K.
Tan, H. C. L.
Sheng, Y. W.
Arshad, M.
Arun, A.
Oh, C. W.
BJU INTERNATIONAL, 2018, 122 : 4 - 4
[30] Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Iyer, Gopa
Balar, Arjun V.
Milowsky, Matthew I.
Bochner, Bernard H.
Dalbagni, Guido
Donat, S. Machele
Herr, Harry W.
Huang, William C.
Taneja, Samir S.
Woods, Michael
Ostrovnaya, Irina
Al-Ahmadie, Hikmat
Arcila, Maria E.
Riches, Jamie C.
Meier, Andreas
Bourque, Caitlin
Shady, Maha
Won, Helen
Rose, Tracy L.
Kim, William Y.
Kania, Brooke E.
Boyd, Mariel E.
Cipolla, Catharine K.
Regazzi, Ashley M.
Delbeau, Daniela
McCoy, Asia S.
Vargas, Hebert Alberto
Berger, Michael F.
Solit, David B.
Rosenberg, Jonathan E.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1949 - +

← 1 2 3 4 5 →